China Shineway Pharmaceutical Group Limited (2877) recorded a turnover of RMB 2,415 million for the nine months ended 30 September 2025, reflecting a 16.3% decrease compared with the same period in 2024. Major product categories all reported lower turnover: injection products amounted to RMB 786 million (down 23.6%), soft capsule products reached RMB 337 million (down 13.7%), granule products registered RMB 391 million (down 14.5%), TCM formula granule products totaled RMB 726 million (down 11.8%), and products in other forms stood at RMB 175 million (down 6.1%).

In terms of product mix, injection products accounted for approximately 32.5% of the total turnover during the period, followed by TCM formula granule products at 30.1%. Soft capsule and granule products accounted for around 14.0% and 16.2%, respectively, while products in other forms represented the remainder, reflecting the group’s diversified product portfolio.